Stock Price, News, Quote and Profile of MIRUM PHARMACEUTICALS INC(NASDAQ:MIRM) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

MIRUM PHARMACEUTICALS INC

NASDAQ:MIRM (5/6/2024, 7:14:41 PM)

After market: 26.39 0 (0%)

26.39

+0.55 (+2.13%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap1.24B

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 249 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. Its development pipeline consists of two clinical-stage product candidates, Livmarli and volixibat. Its product LIVMARLI (maralixibat) oral solution is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) three months of age and older in the United States and for the treatment of cholestatic pruritus in patients with ALGS two months of age and older in Europe. Its second product candidate, Volixibat is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The firm also offers bile acid product portfolio, which includes Cholbam (cholic acid) and Chenodal (chenodiol).